Acamprosate committee review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Forest and Lipha's acamprosate studies demonstrate sufficient efficacy to support approval of the drug for maintenance therapy for alcohol abstinence, FDA's Psychopharmacologic Drugs Advisory Committee concludes in an eight to two vote at its May 10 meetin